WO2001008673A1 - Calcilytic compounds - Google Patents

Calcilytic compounds Download PDF

Info

Publication number
WO2001008673A1
WO2001008673A1 PCT/US2000/020834 US0020834W WO0108673A1 WO 2001008673 A1 WO2001008673 A1 WO 2001008673A1 US 0020834 W US0020834 W US 0020834W WO 0108673 A1 WO0108673 A1 WO 0108673A1
Authority
WO
WIPO (PCT)
Prior art keywords
dimethyl
hydroxy
phenoxy
propyl
cyano
Prior art date
Application number
PCT/US2000/020834
Other languages
English (en)
French (fr)
Inventor
Maxine Gowen
Larry J. Suva
John Fox
George B. Stroup
Edward F. Nemeth
Original Assignee
Smithkline Beecham Corporation
Nps Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MXPA02001204A priority Critical patent/MXPA02001204A/es
Application filed by Smithkline Beecham Corporation, Nps Pharmaceuticals, Inc. filed Critical Smithkline Beecham Corporation
Priority to JP2001513403A priority patent/JP2003505502A/ja
Priority to CA002380081A priority patent/CA2380081A1/en
Priority to PL00353318A priority patent/PL353318A1/xx
Priority to IL14787500A priority patent/IL147875A0/xx
Priority to BR0012921-6A priority patent/BR0012921A/pt
Priority to KR1020027001298A priority patent/KR20020016928A/ko
Priority to EP00952319A priority patent/EP1200076A4/en
Priority to AU65041/00A priority patent/AU764716B2/en
Publication of WO2001008673A1 publication Critical patent/WO2001008673A1/en
Priority to NO20020466A priority patent/NO20020466L/no
Priority to HK02107473.9A priority patent/HK1046238A1/zh
Priority to US11/245,568 priority patent/US20060035927A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PCT/US2000/020834 1999-07-31 2000-07-31 Calcilytic compounds WO2001008673A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
BR0012921-6A BR0012921A (pt) 1999-07-31 2000-07-31 Compostos calcilìticos
JP2001513403A JP2003505502A (ja) 1999-07-31 2000-07-31 カルシリティック化合物
CA002380081A CA2380081A1 (en) 1999-07-31 2000-07-31 Calcilytic compounds
PL00353318A PL353318A1 (en) 1999-07-31 2000-07-31 Calcilytic compounds
IL14787500A IL147875A0 (en) 1999-07-31 2000-07-31 Calcilytic compounds
MXPA02001204A MXPA02001204A (es) 1999-07-31 2000-07-31 Compuestos calciliticos.
KR1020027001298A KR20020016928A (ko) 1999-07-31 2000-07-31 칼시리틱 화합물
EP00952319A EP1200076A4 (en) 1999-07-31 2000-07-31 CALCILYTIC COMPOUNDS
AU65041/00A AU764716B2 (en) 1999-07-31 2000-07-31 Calcilytic compounds
NO20020466A NO20020466L (no) 1999-07-31 2002-01-29 Kalsilytiske forbindelser
HK02107473.9A HK1046238A1 (zh) 1999-07-31 2002-10-15 Calcilytic化合物
US11/245,568 US20060035927A1 (en) 1999-07-31 2005-10-07 Calcilytic compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14677899P 1999-07-31 1999-07-31
US60/146,778 1999-07-31

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10049348 A-371-Of-International 2002-01-30
US10/852,557 Continuation US20040214889A1 (en) 1999-07-31 2004-05-24 Calcilytic compounds

Publications (1)

Publication Number Publication Date
WO2001008673A1 true WO2001008673A1 (en) 2001-02-08

Family

ID=22518969

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/020834 WO2001008673A1 (en) 1999-07-31 2000-07-31 Calcilytic compounds

Country Status (21)

Country Link
EP (1) EP1200076A4 (tr)
JP (1) JP2003505502A (tr)
KR (1) KR20020016928A (tr)
CN (1) CN1367687A (tr)
AU (1) AU764716B2 (tr)
BR (1) BR0012921A (tr)
CA (1) CA2380081A1 (tr)
CO (1) CO5180628A1 (tr)
CZ (1) CZ2002360A3 (tr)
EC (1) ECSP003590A (tr)
HK (1) HK1046238A1 (tr)
HU (1) HUP0202167A3 (tr)
IL (1) IL147875A0 (tr)
MX (1) MXPA02001204A (tr)
NO (1) NO20020466L (tr)
PE (1) PE20010459A1 (tr)
PL (1) PL353318A1 (tr)
TR (1) TR200200278T2 (tr)
UY (1) UY26265A1 (tr)
WO (1) WO2001008673A1 (tr)
ZA (1) ZA200200784B (tr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1254106A1 (en) * 2000-01-24 2002-11-06 SmithKline Beecham Corporation Calcilytic compounds
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US7109238B2 (en) 2000-01-24 2006-09-19 Smith Kline Beecham Corporation Calcilytic compounds
US7205322B2 (en) 2003-02-12 2007-04-17 Bristol-Myers Squibb Company Thiazolidine compounds as calcium sensing receptor modulators
US7265145B2 (en) 2003-05-28 2007-09-04 Bristol-Myers Squibb Company Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method
WO2008077009A1 (en) * 2006-12-18 2008-06-26 Smithkline Beecham Corporation Calcilytic compounds
US7514473B2 (en) 2002-11-26 2009-04-07 Smithkline Beecham, Corp. Calcilytic compounds
WO2013098588A1 (en) * 2011-12-27 2013-07-04 Ubaldo Armato Use of calcilytic drugs as a pharmacological approach to the treatment and prevention of alzheimer's disease, alzheimer's disease-related disorders, and down's syndrome neuropathies
US9861606B2 (en) 2012-09-28 2018-01-09 King's College London Therapeutic for treating inflammatory lung disorders

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108420814A (zh) * 2017-02-15 2018-08-21 四川大学 一种nps-2143用于抗菌的新用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022894A (en) * 1996-04-09 2000-02-08 Nps Pharmaceuticals, Inc. Method of using calcilytic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY121054A (en) * 1998-04-08 2005-12-30 Smithkline Beecham Corp Calcilytic compounds as calcium receptor antagonists.
AR014975A1 (es) * 1998-04-08 2001-04-11 Nps Pharma Inc Compuestos calciliticos, una composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de un medicamento

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022894A (en) * 1996-04-09 2000-02-08 Nps Pharmaceuticals, Inc. Method of using calcilytic compounds

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1254106A4 (en) * 2000-01-24 2005-09-14 Smithkline Beecham Corp CALCILYTIC COMPOUNDS
US7109238B2 (en) 2000-01-24 2006-09-19 Smith Kline Beecham Corporation Calcilytic compounds
EP1254106A1 (en) * 2000-01-24 2002-11-06 SmithKline Beecham Corporation Calcilytic compounds
EP2141146A1 (en) * 2000-01-24 2010-01-06 SmithKline Beecham Corporation Calcilytic compounds
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US8399517B2 (en) 2002-11-26 2013-03-19 GlaxoSmithKline, LLC Calcilytic compounds
US9227914B2 (en) 2002-11-26 2016-01-05 GlaxoSmithKline, LLC Calcilytic compounds
US8980950B2 (en) 2002-11-26 2015-03-17 GlaxoSmithKline, LLC Calcilytic compounds
US7514473B2 (en) 2002-11-26 2009-04-07 Smithkline Beecham, Corp. Calcilytic compounds
US7829594B2 (en) 2002-11-26 2010-11-09 GlaxoSmithKline, LLC Calcilytic compounds
US8586631B2 (en) 2002-11-26 2013-11-19 GlaxoSmithKline, LLC Calcilytic compounds
US7205322B2 (en) 2003-02-12 2007-04-17 Bristol-Myers Squibb Company Thiazolidine compounds as calcium sensing receptor modulators
US7265145B2 (en) 2003-05-28 2007-09-04 Bristol-Myers Squibb Company Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method
US7902394B2 (en) 2006-12-18 2011-03-08 Glaxosmithkline Llc Calcilytic compounds
WO2008077009A1 (en) * 2006-12-18 2008-06-26 Smithkline Beecham Corporation Calcilytic compounds
WO2013098588A1 (en) * 2011-12-27 2013-07-04 Ubaldo Armato Use of calcilytic drugs as a pharmacological approach to the treatment and prevention of alzheimer's disease, alzheimer's disease-related disorders, and down's syndrome neuropathies
US9861606B2 (en) 2012-09-28 2018-01-09 King's College London Therapeutic for treating inflammatory lung disorders

Also Published As

Publication number Publication date
EP1200076A1 (en) 2002-05-02
BR0012921A (pt) 2002-06-18
NO20020466L (no) 2002-03-20
KR20020016928A (ko) 2002-03-06
ZA200200784B (en) 2003-01-29
CO5180628A1 (es) 2002-07-30
AU764716B2 (en) 2003-08-28
MXPA02001204A (es) 2004-05-21
PL353318A1 (en) 2003-11-17
AU6504100A (en) 2001-02-19
PE20010459A1 (es) 2001-06-11
HK1046238A1 (zh) 2003-01-03
ECSP003590A (es) 2002-02-25
EP1200076A4 (en) 2005-02-09
CA2380081A1 (en) 2001-02-08
TR200200278T2 (tr) 2002-06-21
IL147875A0 (en) 2002-08-14
NO20020466D0 (no) 2002-01-29
CN1367687A (zh) 2002-09-04
UY26265A1 (es) 2001-03-16
HUP0202167A3 (en) 2006-07-28
JP2003505502A (ja) 2003-02-12
HUP0202167A2 (en) 2002-10-28
CZ2002360A3 (cs) 2002-10-16

Similar Documents

Publication Publication Date Title
US7576053B2 (en) Methods and compositions for treating degenerative bone disorders
US6221913B1 (en) Dialkyl ureas as calcitonin mimetics
US7507715B2 (en) Methods useful in the treatment of bone resorption diseases
Nemeth Pharmacological regulation of parathyroid hormone secretion
AU764716B2 (en) Calcilytic compounds
EP1070048B1 (en) Calcilytic compounds
Fox Developments in parathyroid hormone and related peptides as bone-formation agents
Shapiro et al. The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta
US20030109537A1 (en) Methods and materials for treating bone conditions
AU3212101A (en) Modulation of bone formation
US20060035927A1 (en) Calcilytic compounds
JP2007523209A (ja) 骨代謝回転が高い個体において骨粗鬆症を治療または予防する方法
CA2288178A1 (en) Piperazine derivatives for treating bone deficit conditions
JP2016538295A (ja) 骨粗鬆症の処置及び予防のためのガストリン拮抗薬
Salt Strontium Ranelate Treatment and Prevention of Osteoporosis, Bone Resorption Inhibitor, Bone Formation Stimulant
CA2346036A1 (en) Methods for regulating bone formation
WO2019022662A1 (en) PREVENTING SIDE EFFECTS IN THE TREATMENT OF CANCER AND FIBROSIS
WO2005030746A1 (en) Calcilytic compounds
Cardinali et al. Melatonin Use as a Bone-Protecting Substance
WO2006042007A2 (en) Chromenone compounds as calcilytics
Chesnut III et al. Clinical Utilization of Salmon Calcitonin in the Treatment of Osteoporosis: Rationale, Supportive Data, and Considerations for the Future
Wos et al. Patent developments in anabolic agents for treatment of bone diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AU BA BB BG BR CA CN CZ DZ EE GE GH GM HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX NO NZ PL RO SG SI SK SL TR TT TZ UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 65041/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/00069/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 516759

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 147875

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 200200784

Country of ref document: ZA

Ref document number: PV2002-360

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1020027001298

Country of ref document: KR

Ref document number: 10049348

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/001204

Country of ref document: MX

Ref document number: 008111774

Country of ref document: CN

Ref document number: 2380081

Country of ref document: CA

Ref document number: 2002/00278

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 2000952319

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020027001298

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000952319

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2002-360

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 65041/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PV2002-360

Country of ref document: CZ